The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.

Victor J. Dzau ([email protected]), National Academy of Medicine, Washington, D.C. J. Michael McGinnis, National Academy of Medicine. In 2016, ahead of the US presidential election, the National ...

Given the prevalence of managed care, it’s incumbent upon the industry to ensure that there is a robust supplier pool.

While evidence-based decisions are essential, they must be paired with effective public messaging that builds trust and ...

Oklahoma and South Carolina are among nine states that use some form of provider-based reference pricing to contain spending ...

We examine key lessons on medical-dental integration from the Program of All-Inclusive Care for the Elderly (PACE), ...

This article does not attempt to predict the potential policies that the new administration and Congress might pursue or how ...

Despite this legal entitlement, many transition-age youth and young adults leaving foster care lose their Medicaid coverage ...

Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...

Expanding eligibility for MSPs is an important avenue to support health care affordability for older low-income adults, ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Paige Nong of the University of Minnesota about her recent paper that evaluates and explores the current use of artificial intelligence and ...